Cure8 research brief
This review summarises the rapidly changing drug landscape for Crohn’s disease and ulcerative colitis, including newly approved biologics and small molecules and several emerging therapies that may affect future treatment options.
It also discusses safety signals (JAK inhibitor boxed warning), comparative trial designs, and the role of biomarkers and treatment positioning.
Clinicians treating IBD, researchers working on IBD therapeutics or biomarkers, patients on biologic or small-molecule therapies, and newly diagnosed patients considering advanced therapy options.
This is a review-style article (abstract-level extraction) summarising mechanisms, pivotal evidence, comparative effectiveness and the pipeline for biologic and small-molecule therapies in IBD.
It highlights newly approved IL-23p19 antagonists, S1P modulators, second-generation JAK inhibitors, emerging agents (anti-TL1A, obefazimod, icotrokinra), head-to-head trials, treat-to-target strategies, and biomarker development. The source appears to be an academic review (Frontiers in Pharmacology) and the extraction is the article abstract.
The content is drawn from the article abstract (structured content depth: abstract). Some trial results mentioned are from conference presentations or company announcements and may not yet be peer-reviewed; the review synthesises available evidence rather than presenting new trial data.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Upadacitinib is already used for some patients with UC and Crohn's; this article offers a structured way to think about why it can act quickly in refractory cases and what evidence would be needed to move from short‑term...
Real-world PSP registries can show how long people stay on vedolizumab and how it’s used alongside or compared with other advanced therapies like tofacitinib. That information can help patients and clinicians understand...
This narrative review surveys novel biomarkers and therapeutic strategies for adult IBD, topics that could affect diagnosis, monitoring, and future treatment options for people with Crohn's disease or ulcerative colitis.
